Levetiracetam reduces myoclonus in corticobasal degeneration

Report of two cases

T. Kovács, Marianna Farsang, Edina Vitaszil, P. Barsi, Tamás Györke, I. Szirmai, A. Kamondi

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Levetiracetam (LEV) has been shown to suppress myoclonus of various origins. Corticobasal degeneration (CBD), a progressive neurodegenerative disorder with Parkinsonian syndrome, is frequently accompanied by myoclonus. We investigated the effect of LEV on myoclonus in two CBD patients. LEV remarkably decreased the myoclonic activity in both patients already at 1,500 mg/day dose. This is the first report on LEV alleviating myoclonus in CBD. Our data indicate that it might be worthwhile to assess this effect in an appropriately designed study.

Original languageEnglish
Pages (from-to)1631-1634
Number of pages4
JournalJournal of Neural Transmission
Volume116
Issue number12
DOIs
Publication statusPublished - Jan 2009

Fingerprint

etiracetam
Myoclonus
Parkinsonian Disorders
Neurodegenerative Diseases

Keywords

  • Corticobasal degeneration
  • Levetiracetam
  • Myoclonus
  • Parkinsonian syndrome

ASJC Scopus subject areas

  • Biological Psychiatry
  • Neurology
  • Clinical Neurology
  • Psychiatry and Mental health

Cite this

Levetiracetam reduces myoclonus in corticobasal degeneration : Report of two cases. / Kovács, T.; Farsang, Marianna; Vitaszil, Edina; Barsi, P.; Györke, Tamás; Szirmai, I.; Kamondi, A.

In: Journal of Neural Transmission, Vol. 116, No. 12, 01.2009, p. 1631-1634.

Research output: Contribution to journalArticle

@article{17e817b6a2214da3b54e0a818fc65345,
title = "Levetiracetam reduces myoclonus in corticobasal degeneration: Report of two cases",
abstract = "Levetiracetam (LEV) has been shown to suppress myoclonus of various origins. Corticobasal degeneration (CBD), a progressive neurodegenerative disorder with Parkinsonian syndrome, is frequently accompanied by myoclonus. We investigated the effect of LEV on myoclonus in two CBD patients. LEV remarkably decreased the myoclonic activity in both patients already at 1,500 mg/day dose. This is the first report on LEV alleviating myoclonus in CBD. Our data indicate that it might be worthwhile to assess this effect in an appropriately designed study.",
keywords = "Corticobasal degeneration, Levetiracetam, Myoclonus, Parkinsonian syndrome",
author = "T. Kov{\'a}cs and Marianna Farsang and Edina Vitaszil and P. Barsi and Tam{\'a}s Gy{\"o}rke and I. Szirmai and A. Kamondi",
year = "2009",
month = "1",
doi = "10.1007/s00702-009-0301-2",
language = "English",
volume = "116",
pages = "1631--1634",
journal = "Journal of Neural Transmission",
issn = "0300-9564",
publisher = "Springer Verlag",
number = "12",

}

TY - JOUR

T1 - Levetiracetam reduces myoclonus in corticobasal degeneration

T2 - Report of two cases

AU - Kovács, T.

AU - Farsang, Marianna

AU - Vitaszil, Edina

AU - Barsi, P.

AU - Györke, Tamás

AU - Szirmai, I.

AU - Kamondi, A.

PY - 2009/1

Y1 - 2009/1

N2 - Levetiracetam (LEV) has been shown to suppress myoclonus of various origins. Corticobasal degeneration (CBD), a progressive neurodegenerative disorder with Parkinsonian syndrome, is frequently accompanied by myoclonus. We investigated the effect of LEV on myoclonus in two CBD patients. LEV remarkably decreased the myoclonic activity in both patients already at 1,500 mg/day dose. This is the first report on LEV alleviating myoclonus in CBD. Our data indicate that it might be worthwhile to assess this effect in an appropriately designed study.

AB - Levetiracetam (LEV) has been shown to suppress myoclonus of various origins. Corticobasal degeneration (CBD), a progressive neurodegenerative disorder with Parkinsonian syndrome, is frequently accompanied by myoclonus. We investigated the effect of LEV on myoclonus in two CBD patients. LEV remarkably decreased the myoclonic activity in both patients already at 1,500 mg/day dose. This is the first report on LEV alleviating myoclonus in CBD. Our data indicate that it might be worthwhile to assess this effect in an appropriately designed study.

KW - Corticobasal degeneration

KW - Levetiracetam

KW - Myoclonus

KW - Parkinsonian syndrome

UR - http://www.scopus.com/inward/record.url?scp=70849091624&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70849091624&partnerID=8YFLogxK

U2 - 10.1007/s00702-009-0301-2

DO - 10.1007/s00702-009-0301-2

M3 - Article

VL - 116

SP - 1631

EP - 1634

JO - Journal of Neural Transmission

JF - Journal of Neural Transmission

SN - 0300-9564

IS - 12

ER -